StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) shareholders

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)

Close on Nov 18, 2026Market cap $1.67BP/E –Yield –

Ownership

Who owns Braveheart Bio's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
13 buys · 0 sales
Net bought $159.03M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with OrbiMed Capital GP IX LLC (13.20%)
12,175,15913.50%13D (active) amendmentSep 8, 2026
AH Bio Fund IV, L.P.
Joint filing with AH Equity Partners Bio IV, L.L.C. (11.40%), Marc L. Andreessen (11.40%) and 1 more
10,232,42011.40%13D (active)Aug 7, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd.7,420,0918.20%13G (passive)Sep 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (8.20%)
7,374,3658.20%13G (passive)Sep 30, 2026
Fhmlsp, L.P.
Joint filing with Frazier Life Sciences Public Fund, L.P. (5.50%), Fhmlsp, L.L.C. (5.50%)
4,976,4575.50%13G (passive)Aug 7, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Travis MurdochCEO and President, Director8,333,6379.26%Aug 7, 2026
Michele A. AndersonChief Development Officer332,1610.37%Aug 7, 2026
James Paul RickeyChief Financial Officer703,5750.78%Aug 7, 2026
Vineeta AgarwalaDirector10,232,42011.36%Aug 14, 2026
Erez ChimovitsDirector, 10% owner273,3330.30%Aug 11, 2026
Genesis GP LLC OrbiMedDirector, 10% owner273,3330.30%Aug 11, 2026
Capital GP IX LLC OrbiMedDirector, 10% owner––Aug 11, 2026
Advisors Llc OrbimedDirector, 10% owner1,102,7391.22%Aug 11, 2026
David Charles LubnerDirector55,5550.06%Aug 7, 2026
Jasper BosDirector––Aug 7, 2026
Christopher ViehbacherDirector759,8570.84%Aug 7, 2026
Tim LohoffDirector––Aug 7, 2026
David I. MalekDirector1,013,2971.13%Aug 7, 2026
Jason V. ColomaDirector1,100,4561.22%Aug 5, 2026
Marc L. Andreessen10% owner9,132,42010.14%Aug 11, 2026
AH Bio Fund IV, L.P.10% owner––Aug 11, 2026
AH Equity Partners Bio IV, L.L.C.10% owner––Aug 11, 2026
Benjamin A. Horowitz10% owner––Aug 11, 2026
Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner7,420,0918.24%Aug 10, 2026
Growth Opportunities Fund III Cooperatief U.A. Forbion10% owner30,331,50233.69%Aug 7, 2026
Growth III Management B.V. Forbion10% owner––Aug 7, 2026
Ventures Fund VII Cooperatief U.A. Forbion10% owner––Aug 7, 2026
Ventures VII Management B.V. Forbion10% owner1,102,7371.22%Aug 7, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Marc L. Andreessen
10% owner
Aug 7, 2026Conversion+9,132,420––9,132,420
Marc L. Andreessen
10% owner
Aug 7, 2026Buy+1,100,000$18.00$19.80M10,232,420
Genesis GP LLC OrbiMed
Director, 10% owner
Aug 7, 2026Buy+273,333$18.00$4.92M273,333
Genesis GP LLC OrbiMed
Director, 10% owner
Aug 7, 2026Conversion+9,132,420––10,235,159
Genesis GP LLC OrbiMed
Director, 10% owner
Aug 7, 2026Buy+1,666,667$18.00$30.00M11,901,826
Erez Chimovits
Director, 10% owner
Aug 7, 2026Buy+273,333$18.00$4.92M273,333
Erez Chimovits
Director, 10% owner
Aug 7, 2026Buy+1,666,667$18.00$30.00M11,901,826
Erez Chimovits
Director, 10% owner
Aug 7, 2026Conversion+9,132,420––10,235,159
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
10% owner
Aug 7, 2026Conversion+7,420,091––7,420,091
James Paul Rickey
Chief Financial Officer
Aug 7, 2026Buy+27,777$18.00$499.99K520,927
David I. Malek
Director
Aug 7, 2026Buy+4,166$18.00$74.99K533,845
Christopher Viehbacher
Director
Aug 7, 2026Buy+83,333$18.00$1.50M609,519
Growth Opportunities Fund III Cooperatief U.A. Forbion
10% owner
Aug 7, 2026Conversion+7,990,867––8,505,478
Growth Opportunities Fund III Cooperatief U.A. Forbion
10% owner
Aug 7, 2026Buy+1,920,000$18.00$34.56M11,640,546
Growth Opportunities Fund III Cooperatief U.A. Forbion
10% owner
Aug 7, 2026Buy+1,680,000$18.00$30.24M10,185,478
Growth Opportunities Fund III Cooperatief U.A. Forbion
10% owner
Aug 7, 2026Conversion+9,132,420––9,720,546
Travis Murdoch
CEO and President, Director
Aug 7, 2026Buy+83,333$18.00$1.50M2,940,670
David Charles Lubner
Director
Aug 7, 2026Buy+55,555$18.00$999.99K55,555
Michele A. Anderson
Chief Development Officer
Aug 7, 2026Buy+1,111$18.00$20.00K332,161

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
28.92%
5M shares short
Days to cover
19.6
At 0M shares a day
Change since last report
+5.1%
From 5M shares
Short volume, 20 days
84.6%
Of volume reported to FINRA

Shares sold short, last 3 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Braveheart Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 106,028 shares on Oct 1, 2026 over the last 90 days.

See a number that looks wrong?